Clinical trials: Sildenafil
Erectile Dysfunction
Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.
This study to will compare the blood levels of sildenafil following administration of an experimental tablet vs. the conventional oral tablet.
- Trial name
- NCT00795938
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
Nurigra Chewable Tablet in Healthy Adult Male Volunteers
The purpose of this study is to evaluate pharmacokinetics of sildenafil citrate in healthy male volunteers.
- Trial name
- NCT01651858
- Testing
- Nurigra Chewable tablet
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Pulmonary Hypertension
Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension
Open label extension study to the pivotal efficacy study to assess the safety of sildenafil citrate in patients with pulmonary arterial hypertension
- Trial name
- NCT00159887
- Testing
- Sildenafil citrate
- Where
- 65 sites in United States, Australia and 20 more
- Volunteers
- 260 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
An Open Label Access Study For Subjects Who Completed A1481156
The purpose of this study is to provide sildenafil therapy to subjects who have completed the A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are judged by the Investigator to derive…
- Trial name
- NCT01582438
- Testing
- Access program - sildenafil citrate, Viagra, Revatio
- Where
- India
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled safety/efficacy database of…
- Trial name
- NCT00796666
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 48 sites in United States, Argentina and 16 more
- Volunteers
- 131 people
- Sponsor
- Pfizer
Hypertension, Pulmonary
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT00853112
- Testing
- PF-00489791, sildenafil
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Obesity
The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity
This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo.
- Trial name
- NCT03364335
- Testing
- Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg
- Where
- 15 sites in United States
- Volunteers
- 267 people
- Sponsor
- NuSirt Biopharma
Impotence
Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire
To evaluate the effectiveness of sildenafil on erectile function and intercourse satisfaction in men with ED as well as to validate the new Sexual Experience Questionnaire which incorporates functional and emotional elements of a…
- Trial name
- NCT00147628
- Testing
- sildenafil citrate
- Where
- 20 sites in United States
- Volunteers
- 209 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
The purpose of this study is to evaluate the effect of macitentan at steady state on the pharmacokinetic (PK) of a single dose of riociguat and sildenafil (Part A); and rosuvastatin (Part B) when co-administered to healthy male…
- Trial name
- NCT04211272
- Testing
- Macitentan, Sildenafil, Riociguat
- Where
- Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Actelion
Microvascular Coronary Artery Disease
Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess the pharmacodynamic effects of SAR247799 on macrovascular endothelial function of the brachial artery using flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03462017
- Testing
- SAR247799, Sildenafil, Acetylcholine
- Where
- 2 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Sanofi
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH)…
- Trial name
- NCT00796510
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 3 sites in United States, Romania and 1 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Erectile Dysfunction
Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products
The study will assess a new biphasic release sildenafil formulation (N4S001), developed by N4 Pharma. The N4S001 tablet contains a total of 100 mg sildenafil.
- Trial name
- NCT03510338
- Testing
- Sublingual sildenafil, Oral sildenafil
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- N4 Pharma UK Ltd.
Hypertension, Pulmonary
Sildenafil IV Bolus Study
The objective of this study is to assess the safety, tolerability and pharmacokinetics of intravenous sildenafil (10 mg) administered as a bolus injection to patients with Pulmonary Arterial Hypertension already receiving and…
- Trial name
- NCT00800592
- Testing
- sildenafil
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.
- Trial name
- NCT00159874
- Testing
- Sildenafil citrate
- Where
- 39 sites in United States, Brazil and 13 more
- Volunteers
- 234 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder
The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored…
- Trial name
- NCT00746967
- Testing
- sildenafil
- Where
- 82 sites in United States
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy Males
Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations
the pharmacokinetics of sildenafil following single doses of sildenafil CT administered with and without water is similar relative to the conventional oral tablet of sildenafil administered with water.
- Trial name
- NCT00902512
- Testing
- Treatment A, Blood samples for the analysis of sildenafil in plasma, Treatment B
- Where
- Mexico
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Hypertension, Familial Persistent, of the Newborn
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
- Trial name
- NCT01720524
- Testing
- iv sildenafil
- Where
- 42 sites in United States, Belgium and 10 more
- Volunteers
- 59 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Impotence
Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection
To determine if men prefer tadalafil or sildenafil for getting and keeping an erection after treatment with both drugs.
- Trial name
- NCT00547092
- Testing
- tadalafil, sildenafil
- Where
- United Kingdom
- Volunteers
- 386 people
- Sponsor
- Eli Lilly and Company
Impotence
Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection
To determine if men with problems getting and keeping an erection prefer treatment with tadalafil or sildenafil.
- Trial name
- NCT00547352
- Testing
- tadalafil, sildenafil
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Spinal Cord Injury, Erectile Dysfunction
A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction
To demonstrate the efficacy, safety and tolerability of sildenafil administered orally, as required, approximately 1 hour prior to sexual activity to men with erectile dysfunction (ED) associated with spinal cord injury (SCI), as…
- Conditions
- Spinal Cord Injury, Erectile Dysfunction, Spinal Cord Trauma, Injuries, Spinal Cord
- Trial name
- NCT00654082
- Testing
- sildenafil
- Where
- 5 sites in Turkey (Türkiye)
- Volunteers
- 88 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.